Investors who lost money on Capricor Therapeutics, Inc.(CAPR) should contact The Gross Law Firm about pending Class Action - CAPR

Core Viewpoint - The Gross Law Firm is notifying shareholders of Capricor Therapeutics, Inc. regarding a potential class action lawsuit due to misleading statements related to the company's drug deramiocel for treating cardiomyopathy associated with Duchenne muscular dystrophy [1][3]. Summary by Sections Class Period and Allegations - The class period for the potential lawsuit is from October 9, 2024, to July 10, 2025 [3]. - Allegations include that Capricor provided investors with misleading information about deramiocel's Biologics License Application (BLA) and concealed adverse facts regarding its Phase 2 HOPE-2 trial safety and efficacy data [3]. FDA Response and Stock Impact - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of effectiveness and the need for additional clinical data [3]. - Following this announcement, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025 [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 15, 2025, to potentially become lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [5].